ARYx Therapeutics Total Long Term Liabilities 2010-2010 | ARYX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ARYx Therapeutics total long term liabilities from 2010 to 2010. Total long term liabilities can be defined as the sum of all non-current liabilities.

ARYx Therapeutics Total Long Term Liabilities 2010-2010 | ARYX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ARYx Therapeutics total long term liabilities from 2010 to 2010. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$173B
Vertex Pharmaceuticals (VRTX)	$129.2B
Bristol Myers Squibb (BMY)	$121.3B
Gilead Sciences (GILD)	$120.8B
CSL (CSLLY)	$91.5B
Regeneron Pharmaceuticals (REGN)	$90.7B
GSK (GSK)	$75.3B
Alnylam Pharmaceuticals (ALNY)	$36.1B
Argenex SE (ARGX)	$35.2B
BioNTech SE (BNTX)	$26.1B
Biogen (BIIB)	$25.1B
Illumina (ILMN)	$24B
BeiGene (BGNE)	$20B
Moderna (MRNA)	$16.5B
Incyte (INCY)	$15.7B
Genmab (GMAB)	$15.4B
Vaxcyte (PCVX)	$12.9B
Insmed (INSM)	$12.8B
BioMarin Pharmaceutical (BMRN)	$12.6B
Bio-Techne Corp (TECH)	$11.9B
Sarepta Therapeutics (SRPT)	$11.3B
Exelixis (EXEL)	$10.3B
Revolution Medicines (RVMD)	$10.2B
QIAGEN (QGEN)	$10.1B
Intra-Cellular Therapies (ITCI)	$9.7B
Exact Sciences (EXAS)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.7B
Repligen (RGEN)	$7.8B
Ascendis Pharma (ASND)	$7.8B